Evidence map›Paper›PMID 30774680›Full record

ArticleIranian journal of pathology2018

Molecular Status of BRAF Mutation in Prostate Adenocarcinoma: The Analysis of 100 Cases in North-East of IRAN.

Amir Hossein Jafarian, Khatoone Mirshekar Nasirabadi, Sare Etemad, Masoumeh Jafaripour, Mansoore Darijani, Maryam Sheikhi, Hossein Ayatollahi, Sepideh Shakeri, Seyyede Fatemeh Shams, Saeed Davari

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Iranian journal of pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Expression of MutatedVeterinary sciences · 2024
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Amir Hossein JafarianCancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Khatoone Mirshekar NasirabadiCancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Sare EtemadCancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Masoumeh JafaripourCancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mansoore DarijaniCancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Maryam SheikhiCancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Hossein AyatollahiCancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Sepideh ShakeriCancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Seyyede Fatemeh ShamsCancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Saeed DavariCancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mashhad University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objective

methodsIn this retrospective study, we gathered 100 formalin-fixed paraffin-embedded samples of prostate adenocarcinoma. A hundred archived samples of adjacent benign prostatic hyperplasia were chosen as normal control. This study was done in pathology laboratory of Qaem Hospital during 2013-2015.

resultsTotal number of 200 PC and normal cases was investigated for BRAF V600E mutation. The BRAF V600E mutation was found in only 4 patients but it was not detected in normal cases. There were no significant differences between patient and control groups for this mutation (

conclusionAccording to our findings, BRAF gene mutations did not play essential role in PC. Therefore, anti-BRAF (V600E) could not be considered as a proper target for therapy.

Indexed as

BRAF mutationGleason scoreProstate adenocarcinoma

Identifiers

PMID30774680
PMCPMC6358555
OpenAlexW2896338885

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.